Efficacy of Tyrosine Kinase Inhibitor Combined with Decitabine, Homoharringtonine, Interferon in the Maintenance Therapy of Blast Phase Chronic Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2023.03.005
- Author:
Zhi-Yue LI
1
;
Hui-Fang ZHAO
1
;
Yan-Li ZHANG
1
;
Yong-Ping SONG
2
Author Information
1. Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China.
2. Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China,E-mail: songyongping001@126.com.
- Publication Type:Journal Article
- Keywords:
blast phase;
chronic myeloid leukemia;
decitabine;
homoharringtonine;
interferon;
maintenance therapy;
tyrosine kinase inhibitor
- MeSH:
Humans;
Middle Aged;
Blast Crisis/drug therapy*;
Homoharringtonine/therapeutic use*;
Decitabine/therapeutic use*;
Interferons/therapeutic use*;
Tyrosine Protein Kinase Inhibitors;
Retrospective Studies;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Protein Kinase Inhibitors/therapeutic use*;
Treatment Outcome
- From:
Journal of Experimental Hematology
2023;31(3):649-653
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the efficacy of tyrosine kinase inhibitor (TKI) combined with decitabine, homoharringtonine, and interferon regimen as maintenance therapy for blast phase chronic myeloid leukemia (CML-BP).
METHODS:The clinical data of CML-BP patients who received the first major hematological response after induction therapy at The Affiliated Cancer Hospital of Zhengzhou University from June 2015 to December 2021 were analyzed retrospectively. The event-free survival, duration of remission, and overall survival of patients in TKI combined with decitabine, homoharringtonine, interferon group(n=18) and TKI combined with conventional chemotherapy group(n=10) were compared by log-rank test.
RESULTS:A total of 28 patients were included, with a median age of 46 (24-58) years old. Kaplan-Meier survival analysis showed that patients in TKI combined with decitabine, homoharringtonine, interferon group had longer event-free survival (7.4 vs 4.3 months, P=0.043, HR＝0.44, 95% CI: 0.17-1.14), duration of overall remission (16.1 vs 6.6 months, P=0.005, HR＝0.32, 95% CI: 0.11-0.89), overall survival (34.3 vs 13.5 months, P=0.006, HR＝0.29, 95% CI: 0.10-0.82) compared with patients in TKI combined with conventional chemotherapy group.
CONCLUSION:The TKI combined with decitabine, homoharringtonine and interferon regimen can significantly prolong the survival of CML-BP patients who obtained the major hematological response compared with TKI combined with conventional chemotherapy regimen.
